DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)

Market Cap	192.68B -25.8%
Revenue (ttm)	148.75B -5.3%
Net Income	4.43B +3.8%
EPS	247.96 +4.0%
Shares Out	17.52M
PE Ratio	44.36
Forward PE	n/a
Dividend	150.00 (1.36%)
Ex-Dividend Date	Jun 29, 2026

Volume	76,485
Open	11,050
Previous Close	11,000
Day's Range	10,640 - 11,090
52-Week Range	7,460 - 24,900
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About DAE HWA Pharmaceutical

DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, u...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 308
• Stock Exchange: KOSDAQ
• Ticker Symbol: 067080

Financial Performance

In 2025, DAE HWA Pharmaceutical's revenue was 143.06 billion, a decrease of -4.25% compared to the previous year's 149.41 billion. Earnings were 1.65 billion, an increase of 211.15%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 12, 2026

Data Sources Report a data error